eXoZymes (EXOZ) Competitors $9.70 -0.29 (-2.90%) As of 12:37 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock EXOZ vs. IVA, ARCT, ABEO, NBTX, RCKT, ALDX, AMRN, BNTC, IMAB, and INBXShould you be buying eXoZymes stock or one of its competitors? The main competitors of eXoZymes include Inventiva (IVA), Arcturus Therapeutics (ARCT), Abeona Therapeutics (ABEO), Nanobiotix (NBTX), Rocket Pharmaceuticals (RCKT), Aldeyra Therapeutics (ALDX), Amarin (AMRN), Benitec Biopharma (BNTC), I-Mab (IMAB), and Inhibrx Biosciences (INBX). These companies are all part of the "pharmaceutical products" industry. eXoZymes vs. Its Competitors Inventiva Arcturus Therapeutics Abeona Therapeutics Nanobiotix Rocket Pharmaceuticals Aldeyra Therapeutics Amarin Benitec Biopharma I-Mab Inhibrx Biosciences eXoZymes (NASDAQ:EXOZ) and Inventiva (NASDAQ:IVA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations. Is EXOZ or IVA more profitable? Inventiva's return on equity of 0.00% beat eXoZymes' return on equity.Company Net Margins Return on Equity Return on Assets eXoZymesN/A -134.50% -81.63% Inventiva N/A N/A N/A Do insiders & institutionals believe in EXOZ or IVA? 19.1% of Inventiva shares are owned by institutional investors. 72.4% of eXoZymes shares are owned by company insiders. Comparatively, 32.0% of Inventiva shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has higher valuation & earnings, EXOZ or IVA? eXoZymes has higher earnings, but lower revenue than Inventiva. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioeXoZymes$70K1,162.61-$5.86MN/AN/AInventiva$9.95M41.92-$199.34MN/AN/A Do analysts rate EXOZ or IVA? Inventiva has a consensus target price of $10.40, indicating a potential upside of 138.53%. Given Inventiva's stronger consensus rating and higher probable upside, analysts clearly believe Inventiva is more favorable than eXoZymes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Inventiva 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Does the media prefer EXOZ or IVA? In the previous week, eXoZymes and eXoZymes both had 3 articles in the media. Inventiva's average media sentiment score of 1.40 beat eXoZymes' score of 1.15 indicating that Inventiva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment eXoZymes 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inventiva 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryInventiva beats eXoZymes on 8 of the 11 factors compared between the two stocks. Get eXoZymes News Delivered to You Automatically Sign up to receive the latest news and ratings for EXOZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EXOZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXOZ vs. The Competition Export to ExcelMetriceXoZymesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$81.38M$3.13B$5.68B$9.80BDividend YieldN/A2.23%4.61%4.07%P/E RatioN/A20.7930.6825.54Price / Sales1,162.61371.51464.31116.56Price / CashN/A43.0338.2159.48Price / Book11.288.639.006.14Net Income-$5.86M-$54.65M$3.25B$264.89M7 Day Performance-1.42%6.60%4.78%2.68%1 Month Performance-2.02%9.58%6.74%3.07%1 Year PerformanceN/A14.06%30.51%25.06% eXoZymes Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXOZeXoZymesN/A$9.70-2.9%N/AN/A$81.38M$70K0.0029News CoverageEarnings ReportIVAInventiva3.6287 of 5 stars$3.64+4.0%$10.40+185.7%+93.6%$334.82M$9.95M0.00100Positive NewsShort Interest ↓Gap DownARCTArcturus Therapeutics2.8717 of 5 stars$11.98-1.9%$54.00+350.8%+0.1%$331.14M$152.31M-4.74180Earnings ReportAnalyst ForecastAnalyst RevisionABEOAbeona Therapeutics4.2847 of 5 stars$6.27-1.9%$19.25+207.0%+46.1%$326.89M$3.50M-4.9490Trending NewsEarnings ReportAnalyst ForecastNBTXNanobiotix0.6777 of 5 stars$7.19+4.2%$8.00+11.3%+70.5%$325.22M$39.18M0.00100Short Interest ↑RCKTRocket Pharmaceuticals4.8425 of 5 stars$3.09+2.3%$17.87+478.2%-83.4%$322.49MN/A-1.17240Analyst RevisionALDXAldeyra Therapeutics2.2694 of 5 stars$5.17-1.0%$9.50+83.8%+13.0%$312.65MN/A-5.3310News CoverageInsider TradeAnalyst RevisionAMRNAmarin0.2075 of 5 stars$15.10+0.3%$12.00-20.5%+23.0%$311.64M$228.61M-4.11360BNTCBenitec Biopharma1.798 of 5 stars$11.75+0.9%$26.00+121.3%+45.0%$305.82M$80K-7.7820News CoverageIMABI-Mab2.334 of 5 stars$3.51-6.1%$6.00+70.9%+386.8%$304.81M$3.89M0.00380Positive NewsINBXInhibrx Biosciences2.003 of 5 stars$21.34+1.7%N/A+112.0%$303.70M$200K0.18166News CoverageEarnings ReportShort Interest ↓ Related Companies and Tools Related Companies Inventiva Competitors Arcturus Therapeutics Competitors Abeona Therapeutics Competitors Nanobiotix Competitors Rocket Pharmaceuticals Competitors Aldeyra Therapeutics Competitors Amarin Competitors Benitec Biopharma Competitors I-Mab Competitors Inhibrx Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EXOZ) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding eXoZymes Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share eXoZymes With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access